Pancreatic Neoplasm Clinical Trial
Official title:
Pancreatic Cyst DNA Analysis
The purpose of this study is to assist with early and accurate diagnosis of cancer in pancreatic cysts based on the analysis of DNA obtained by endoscopic ultrasound guided fine needle aspiration
The study of pancreatic diseases is hindered by the organ's deep seated location and
especially lack of symptoms during the early stages of disease development and progression
e.g. pancreatic cancer. This is particularly true of pancreatic cysts, the variety and the
malignant potential of which encompass a broad spectrum. The radiological features
distinguishing a benign from a pre-malignant to a frankly malignant cyst in the pancreas are
frequently underwhelming and have lead to the clinical practice of sampling all but the most
obvious. The yield of the aspirate in turn is frequently not of a quality upon which a
clinical decision can be based.
Most would agree that the best approach for management of pancreatic cystic neoplasm lies in
early diagnosis, ideally at a precancerous stage. The effectiveness and applicability of
this study is the based on the ability of the cyst DNA analysis to stratify the patients at
risk of developing pancreatic cancer based on the extent of accumulated mutational damage.
;
Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01354795 -
Prospective Study Comparing Methods of Obtainment of Specimen After EUS-FNA in Patients With Peri-pancreatic Mass
|
N/A | |
Completed |
NCT00958841 -
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
|
Phase 2 | |
Terminated |
NCT00249301 -
A Study of MLN8054 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06122896 -
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
|
Early Phase 1 | |
Terminated |
NCT02602067 -
131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients
|
Phase 1 | |
Recruiting |
NCT06411795 -
Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy
|
Phase 2 | |
Completed |
NCT03622229 -
EUS-FNB for Solid Pancreatic Lesions: Side-fenestrated Vs Fork-tip Needle
|
N/A | |
Recruiting |
NCT06400472 -
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT02791503 -
CROSSFIRE Trial: Comparing the Efficacy of Irreversible Electroporation With Radiotherapy
|
N/A | |
Recruiting |
NCT05786716 -
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations
|
Phase 2/Phase 3 | |
Completed |
NCT05745415 -
Cancer Stem Cell Specific Aptamer's Ability to Detect Blood Circulating Cancer Stem Cells and Its Role as a Predictor of Prognosis in Pancreatic Cancer
|
||
Completed |
NCT03322592 -
EUS-FNB With ROSE Vs. EUS-FNB Without ROSE
|
N/A | |
Recruiting |
NCT05083247 -
Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma
|
Phase 2 | |
Completed |
NCT00436423 -
A Phase Ⅱ Study of Gemcitabine Combination With TS-1 in Patient With Advanced or Recurred Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT02900950 -
Multicolour Versus Monocolour Specimens Inking After Pancreaticoduodenectomy for Periampullary Cancer
|
N/A | |
Completed |
NCT00711191 -
A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas
|
Phase 1 | |
Completed |
NCT00034281 -
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2
|
Phase 1 | |
Completed |
NCT00005926 -
Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas
|
Phase 2 | |
Recruiting |
NCT04164017 -
Impact of Suction in the EUS-guided Fine Needle Biopsy of Solid Pancreatic Lesions
|
N/A | |
Recruiting |
NCT05687123 -
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
|
Phase 1 |